Related Experiment Video
Updated: Mar 27, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity
Ted G Laderas1, Laura M Heiser2, Kemal Sönmez2
1OHSU Knight Cancer Institute, Oregon Health & Science University, PortlandOR, USA; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, PortlandOR, USA.
Abstract:
Tumorigenesis is a multi-step process, involving the acquisition of multiple oncogenic mutations that transform cells, resulting in systemic dysregulation that enables proliferation, invasion, and other cancer hallmarks. The goal of precision medicine is to identify therapeutically-actionable mutations from large-scale omic datasets. However, the multiplicity of oncogenes required for transformation, known as oncogenic collaboration, makes assigning effective treatments difficult. Motivated by this observation, we propose a new type of oncogenic collaboration where mutations in genes that interact with an oncogene may contribute to the oncogene's deleterious potential, a new genomic feature that we term "surrogate oncogenes." Surrogate oncogenes are representatives of these mutated subnetworks that interact with oncogenes. By mapping mutations to a protein-protein interaction network, we determine the significance of the observed distribution using permutation-based methods. For a panel of 38 breast cancer cell lines, we identified a significant number of surrogate oncogenes in known oncogenes such as BRCA1 and ESR1, lending credence to this approach. In addition, using Random Forest Classifiers, we show that these significant surrogate oncogenes predict drug sensitivity for 74 drugs in the breast cancer cell lines with a mean error rate of 30.9%. Additionally, we show that surrogate oncogenes are predictive of survival in patients. The surrogate oncogene framework incorporates unique or rare mutations from a single sample, and therefore has the potential to integrate patient-unique mutations into drug sensitivity predictions, suggesting a new direction in precision medicine and drug development. Additionally, we show the prevalence of significant surrogate oncogenes in multiple cancers from The Cancer Genome Atlas, suggesting that surrogate oncogenes may be a useful genomic feature for guiding pancancer analyses and assigning therapies across many tissue types.
Insights
We introduce "surrogate oncogenes," mutated genes interacting with known oncogenes, to improve cancer treatment. This approach predicts drug sensitivity and patient survival, offering new avenues for precision medicine and drug development.
Area of Science:
- Genomics
- Cancer Biology
- Computational Biology
Background:
- Tumorigenesis involves multiple oncogenic mutations, complicating precision medicine.
- Oncogenic collaboration, where multiple mutations drive cancer, poses treatment challenges.
- Identifying therapeutically-actionable mutations from omic data is crucial for targeted therapies.
Purpose of the Study:
- To propose and validate a novel genomic feature, "surrogate oncogenes," representing mutated subnetworks interacting with known oncogenes.
- To assess the utility of surrogate oncogenes in predicting drug sensitivity and patient survival in breast cancer.
- To explore the prevalence and potential application of surrogate oncogenes across multiple cancer types.
Main Methods:
- Mapping mutations to protein-protein interaction networks.
- Utilizing permutation-based methods to determine the statistical significance of surrogate oncogenes.
- Employing Random Forest Classifiers to predict drug sensitivity and survival outcomes.
- Analyzing data from breast cancer cell lines and The Cancer Genome Atlas (TCGA).
Main Results:
- Identified significant surrogate oncogenes interacting with known oncogenes like BRCA1 and ESR1 in breast cancer cell lines.
- Demonstrated that surrogate oncogenes predict drug sensitivity for 74 drugs with a mean error rate of 30.9%.
- Showed surrogate oncogenes are predictive of patient survival and are prevalent across multiple cancer types.
Conclusions:
- Surrogate oncogenes represent a novel genomic feature that captures oncogenic collaboration.
- This framework enhances drug sensitivity prediction and survival analysis, offering a new direction for precision medicine.
- Surrogate oncogenes have potential for guiding pan-cancer analyses and therapy assignment across diverse cancer types.
Related Concept Videos
Treatment Resistant Cancers
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Emax Drug–Concentration Effect Model

